Company: NCNA
Filing Date: 2025-03-20
Form Type: 20-F
Source: 0000950170-25-042709
Chunk: 140

Company: NuCana plc
Filing Date: 2025-03-20
Form: 20-F
Item: Item 4
Chunk 140
---
 Module 1 included 12 patients with a variety of solid tumors who had exhausted all other treatment options. The majority of patients, 75%, had received prior PD-1 inhibitor-based therapy. The combination of NUC-3373 plus pembrolizumab was generally well tolerated. Encouraging signals of anti-cancer activity were observed with confirmed Partial Responses in 2 patients and Stable Disease in a further 4 patients, resulting in an objective response rate of 22% and a disease control rate of 67% in the efficacy evaluable population. Two patient case studies were highlighted from Module 1. A patient with urothelial bladder cancer who had previously received gemcitabine plus cisplatin followed by the PD-L1 inhibitor atezolizumab achieved a partial response and remained on therapy for 23 months. Following treatment with NUC-3373 plus pembrolizumab, the patient achieved 100% reduction in the target lesion, considered a confirmed partial response due to the presence of non-target lesions, and has remained on treatment for over 10 months. The second case study was a patient with BRAF mutant metastatic cutaneous melanoma who had previously received pembrolizumab with a best response of progressive disease within 5 months. This was followed by dabrafenib plus trametinib where trametinib was discontinued after 1 month due to toxicity and achieved stable disease before progressing after 7 years on dabrafenib. Following treatment with NUC-3373 plus pembrolizumab, this patient achieved a confirmed Partial Response with an 81% reduction in the target lesion and remains on treatment for over 12 months.
 Module 2 included 4 patients with non-small cell lung cancer, or NSCLC, or pleural mesothelioma who had disease progression on, or were unable to tolerate, prior chemotherapy-containing regimens. Docetaxel is the current standard of care for NSCLC patients without targetable alterations who progress on PD-1 inhibitor-based therapy, however, it is associated with modest clinical benefit with a median PFS of 3-4 months and substantial toxicity. Following treatment of the first 4 patients in this module, enrollment was put on hold due to toxicity challenges with docetaxel. Despite this, 2 patients achieved prolonged Stable Disease. Two patient case studies were highlighted from Module 2. A patient with pleural mesothelioma who had previously received carboplatin plus pemetrex